tag:blogger.com,1999:blog-6173393362223742012.post6089074031182117736..comments2023-08-24T08:30:25.608-07:00Comments on Gene Sherpas: Personalized Medicine and You: Good Enough Science? Apparently so at 23andmeSteve Murphy MDhttp://www.blogger.com/profile/11774190000307343476noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-6173393362223742012.post-88571388408917419212009-11-08T05:40:28.345-08:002009-11-08T05:40:28.345-08:00Dear Steve,As you know, the business model of DTC ...Dear Steve,<br><br>As you know, the business model of DTC genetics companies is not to take care of patients, but sell genetic data to big pharma in the end. Their business model is based on genotyping the maximum number of customers possible, even if they loss money in the process, and offer their data to big pharma. The role of investors in the meantime is to make possible this business model, investing money to allow the DTC companies survive. <br><br>They use internet because is a good way to get a lot of customers from all around the world very quickly.<br><br>¿How does big pharma get the genetic data of people? In order to do this legally, DTC genetics companies would be sold to big pharma. That’s legal, and it is a pure speculative way to make money, playing with the health of people and their personal data. DTC companies would get a lot of money for the sale, enough to pay off their investors a lot of money and keep everybody happy.<br><br>Genentech is investor of 23andme, and Genentech is owned by Roche.<br><br>Do you think Roche or any big pharma company may be interested in buying 23andme in the future?<br><br>If so, for what purpose? Which advantages would get big pharma by owning poor genetic data of healthy people with phenotypic data obtained from self-questionnaires?<br><br>Are DTC genetics companies making a great mistake if they think their data is going to be of interest to big pharma?Anonymousnoreply@blogger.com